Analysts have clear opinions on ATNX.
Based on 2 analysts offering 12 month price targets for Athenex in the last 3 months. The average price target is $30.50 with a high forecast of $31.00 and a low forecast of $30.00. The average price target represents a 90.74% increase from the last pric
Athenex, Inc. (ATNX) is followed by 2 analysts on the street. Their average price target to be reached in the next 12 months has a
Kennen MacKay from RBC Capital rates it a Buy with a target of $31.00.
Similarly, 12 days ago Chad Messer of Needham Reiterated a Buy with a target of $30.00.
The consensus on the street is Moderate Buy.
What does Athenex, Inc.(ATNX) do ?
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer.It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Pl
Athenex, Inc.(ATNX) Insider Trades
Multiple company employees have indulged in significant insider trading. Athenex, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that:
Dir, Fok Manson : P – Purchase(+$583,500) of ATNX in the trading session of 2019-11-07.
10% Perceptive Advisors LLC : P – Purchase(+$546,500) of ATNX in the trading session of 2019-10-17.
10% Perceptive Advisors LLC : P – Purchase(+$691,714) of Athenex, Inc. in the trading session of 2019-10-16.